Cancer therapies are, increasingly, throwing one-two punches at cancer. For example, Sutro Biopharma presented Phase I data at the American Association for Cancer Research (AACR) Annual Meeting on April 8 showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death. “STRO-002 is in phase I trials for ovarian and endometrial cancer. It’s a […]

New data from the open-label extension trial of the phase 2 RESCUE-ALS study (NCT04098406) for amyotrophic lateral sclerosis (ALS) suggest nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) slows clinical decline. RESCUE-ALS is a phase 2 study that is not powered for statistical analysis of survival. Using the European Network for the Cure of […]

A novel treatment for amyotrophic lateral sclerosis (ALS) that targets brain cell energy production to promote remyelination showed signs of efficacy in a phase 2 trial, though it did not meet its primary endpoint, which was the change in the summated motor unit index (MUNIX) from baseline to week 36. The drug, CNM-Au8, is being developed by […]